Topical application of lidocaine or bupivacaine in the healing of surgical wounds in dogs

Minto, Bruno Watanabe; Zanato, Laura; Franco, Guilherme Galhardo; Kawamoto, Fernando Yoiti Kitamura; Borsaro, Camila Potério; Pazzini, Josiane Morais; Carvalho, Elizabeth Regina; Matsui, Andresa

doi:10.1590/s0102-865020200070000001

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first step in the treatment protocol is to apply the lidocaine formulation to the periwound 5 min prior to debridement, if debridement is required [ 25 , 26 ]. The OCM product is applied next, directly onto the wound bed.…”

Section: A Combination Therapy Protocol For Chronic Wound Carementioning

confidence: 99%

A Novel Comprehensive Therapeutic Approach to the Challenges of Chronic Wounds: A Brief Review and Clinical Experience Report

Bettle,

Bell,

Bakewell

2023

Adv Ther

View full text Add to dashboard Cite

Following the clinical perspective and concept that a healthy body will not develop chronic wounds, the central approach for the treatment described here is based on an understanding of how the body transforms the wound microenvironment from a non-healing to a healing state. As part of a comprehensive treatment regimen that includes OCM™ (complete matrix), wound preparation, and skin protectant formulations, the OCM contains components for complete wound healing by attending to the individual needs required to promote the closure of each unique chronic wound. During application of the comprehensive treatment regimen in independent investigator-led trials, the total wound percentage average reduction over the first 4 weeks of treatment was 60% across multiple wound types; median time to total wound closure was 6.9 weeks. Safety testing of the OCM formulation shows no potential allergenicity, no potential sensitization, and no known product-related adverse events. Clinical trials evaluating the OCM formulation as part of the comprehensive treatment regimen of multiple wound types are underway. Results of clinical trials and real-world experiences will expand current knowledge of the wound-healing potential of this novel product.

show abstract

Section: A Combination Therapy Protocol For Chronic Wound Carementioning

confidence: 99%

A Novel Comprehensive Therapeutic Approach to the Challenges of Chronic Wounds: A Brief Review and Clinical Experience Report

Bettle,

Bell,

Bakewell

2023

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Bupivacaine is a local anesthetic from the amide class [14] with high potency [15] and a long duration of action [16], which is also notable for its analgesic and antibacterial effects [14,16]. Animal studies have shown that bupivacaine accelerates the vascularization and healing of surgical wounds [17]. Analysis performed on rats demonstrated the analgesic action of bupivacaine by reducing pain in burn wounds [14,18].…”

Section: Introductionmentioning

confidence: 99%

Development and Optimization of Chitosan-Hydroxypropyl Methylcellulose In Situ Gelling Systems for Ophthalmic Delivery of Bupivacaine Hydrochloride

et al. 2021

View full text Add to dashboard Cite

The aim of this study was the development and optimization of chitosan and hydroxypropyl methylcellulose (HPMC) in situ gelling systems, loaded with bupivacaine hydrochloride for topical ocular administration. This study is based on the properties of two polymers: chitosan, which has mucoadhesive action and is a pH-sensitive polymer, but also the cellulose derivative hydroxypropyl methylcellulose, a thermosensitive polymer which has mucoadhesive properties and increases the viscosity of systems. The analysis and optimization of in situ gelling systems were performed based on an experimental design and response surface methodology. The following formulation parameters were considered: X1 = chitosan concentration (0.5%, 1%), X2 = HPMC E 5 LV concentration (2%, 5%) and X3 = Chitosan/HPMC E 5 LV ratio (1/1, 2/1). In addition, the parameters to be optimized were represented by the contact angle (CA (°)), viscosity and cumulative percentage of bupivacaine hydrochloride released in vitro. The results indicate that the designed in situ gelling systems are suitable for bupivacaine prolonged ophthalmic release and overcome the principal disadvantages of the liquid’s ocular formulations. An immediate therapeutic effect corresponding to ocular anesthetic installation was assured in the first stage: burst bupivacaine release. In the second phase, the gradual drug release was assured for over 6 h. This drug release profile, together with the corresponding rheological profile and a collection of superficial properties for good ocular adhesion balanced with an adequate hydrophilic character, assured the desired quality of the attributes for the proposed systems. The system, based on chitosan 1%, HPMC E 5 LV 5% and a 1/1 polymer ratio, could be a solution for the proposed formulation of in situ gelling colloidal systems, since the viscosity of the system was within the range of the optimal viscosity of the eye, and the amount of bupivacaine hydrochloride released after 6 h was the highest at 69.55%.

show abstract

Local Anesthesia

Norkus¹

2023

Advanced Monitoring and Procedures for Small Animal Emergency and Critical Care

View full text Add to dashboard Cite

Topical application of lidocaine or bupivacaine in the healing of surgical wounds in dogs

Cited by 5 publications

References 21 publications

A Novel Comprehensive Therapeutic Approach to the Challenges of Chronic Wounds: A Brief Review and Clinical Experience Report

A Novel Comprehensive Therapeutic Approach to the Challenges of Chronic Wounds: A Brief Review and Clinical Experience Report

Development and Optimization of Chitosan-Hydroxypropyl Methylcellulose In Situ Gelling Systems for Ophthalmic Delivery of Bupivacaine Hydrochloride

Local Anesthesia

Contact Info

Product

Resources

About